BR0313674A - Composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou a profilaxia de um distúrbio afetivo relacionado com a tensão - Google Patents

Composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou a profilaxia de um distúrbio afetivo relacionado com a tensão

Info

Publication number
BR0313674A
BR0313674A BR0313674-4A BR0313674A BR0313674A BR 0313674 A BR0313674 A BR 0313674A BR 0313674 A BR0313674 A BR 0313674A BR 0313674 A BR0313674 A BR 0313674A
Authority
BR
Brazil
Prior art keywords
compound
prophylaxis
treatment
affective
pamoate
Prior art date
Application number
BR0313674-4A
Other languages
English (en)
Inventor
Camille Georges Wermuth
Original Assignee
Prestwick Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prestwick Pharmaceuticals Inc filed Critical Prestwick Pharmaceuticals Inc
Publication of BR0313674A publication Critical patent/BR0313674A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, MéTODO PARA O TRATAMENTO OU A PROFILAXIA DE UM DISTúRBIO AFETIVO RELACIONADO COM A TENSãO". Os novos sais de pamoato de certas 3-fenil-3-dimetilaminoalquil-4,4-dimetilpiperidin-2,6-dionas (I) e solvatos farmacologicamente aceitáveis destes são destituídos da perda de peso e das mudanças de hepatócitos no rato que limitou-se a níveis marginalmente efetivos das doses clínicas permitidas dos cloridretos correspondentes no tratamento ou profilaxia de distúrbios afetivos relacionados com a tensão tais como ansiedade, depressão, enxaqueca e apnéia do sono. Os sais de pamoato preferidos são o pamoato de 3-(3,5-dimetoxifenil)-3-(3-dimetilaminopropil)-4,4-dimetilpiperidina-2,6- diona e, especialmente o pamoato de 3-(3-metoxifenil)-3-(3-dimetilaminopropil)-4,4-dimetilpiperidina-2,6-dio na.
BR0313674-4A 2002-08-22 2003-08-18 Composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou a profilaxia de um distúrbio afetivo relacionado com a tensão BR0313674A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0219639.2A GB0219639D0 (en) 2002-08-22 2002-08-22 Novel piperidin-2,6-dione salts and their use for the treatment of stress-related affective disorders
PCT/IB2003/003698 WO2004017970A1 (en) 2002-08-22 2003-08-18 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders

Publications (1)

Publication Number Publication Date
BR0313674A true BR0313674A (pt) 2005-06-21

Family

ID=9942831

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313674-4A BR0313674A (pt) 2002-08-22 2003-08-18 Composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou a profilaxia de um distúrbio afetivo relacionado com a tensão

Country Status (23)

Country Link
US (2) US7514454B2 (pt)
EP (1) EP1539160B1 (pt)
JP (1) JP2005538146A (pt)
KR (1) KR20050038014A (pt)
CN (1) CN1678316A (pt)
AT (1) ATE330605T1 (pt)
BR (1) BR0313674A (pt)
CA (1) CA2495377A1 (pt)
CY (1) CY1105541T1 (pt)
DE (1) DE60306396T2 (pt)
DK (1) DK1539160T3 (pt)
EA (1) EA007900B1 (pt)
ES (1) ES2268474T3 (pt)
GB (1) GB0219639D0 (pt)
GE (1) GEP20074051B (pt)
IL (1) IL166941A (pt)
MX (1) MXPA05001919A (pt)
NO (1) NO20051471L (pt)
NZ (1) NZ538341A (pt)
PL (1) PL373416A1 (pt)
PT (1) PT1539160E (pt)
UA (1) UA80144C2 (pt)
WO (1) WO2004017970A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
GB0518763D0 (en) * 2005-09-14 2005-10-19 Prestwick Pharmaceuticals Inc Treatment of hypertension
BRPI0702900A2 (pt) * 2006-06-28 2011-03-15 Teva Pharma formas cristalinas da atorvastatina
WO2013150052A1 (en) 2012-04-04 2013-10-10 Intervet International B.V. Soft chewable pharmaceutical products
CN105727117A (zh) * 2016-02-03 2016-07-06 瓮杰林 一种治疗前列腺增生的药物及其制备方法
CN106831594B (zh) * 2017-01-18 2018-02-02 力赛生物医药科技（厦门）有限公司 可乐定双羟萘酸盐及其制备方法
CN115702894A (zh) * 2021-08-11 2023-02-17 朱信红 一种用于止吐的缓释组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1455687A (en) * 1972-12-28 1976-11-17 Aspro Nicholas Ltd Pharmacologically active 3-phenyl-3-aminoalkyl-2,6-dioxo-hydro genated pyridines
US4461771A (en) * 1983-03-01 1984-07-24 Gittos Maurice W Treatment of migraine with dioxopiperidine derivatives
DE3686622T2 (de) * 1985-09-11 1993-04-01 British Tech Group Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
GB2196251B (en) 1986-09-08 1990-07-04 Nat Res Dev Anxiolytic compositions containing dioxopiperidine derivatives
GB8716338D0 (en) 1987-07-10 1987-08-19 Nat Res Dev Anti-anxiogenic compositions
GB2379216A (en) * 2001-08-28 2003-03-05 Maurice Ward Gittos Piperidin-2,6-dione salts useful for the treatment of stress-related affective disorders

Also Published As

Publication number Publication date
IL166941A (en) 2010-04-15
MXPA05001919A (es) 2005-06-03
JP2005538146A (ja) 2005-12-15
EP1539160B1 (en) 2006-06-21
DE60306396T2 (de) 2007-05-03
NZ538341A (en) 2006-09-29
PL373416A1 (en) 2005-08-22
PT1539160E (pt) 2006-10-31
EA007900B1 (ru) 2007-02-27
EP1539160A1 (en) 2005-06-15
GEP20074051B (en) 2007-02-26
DK1539160T3 (da) 2006-10-09
US7514454B2 (en) 2009-04-07
US20090182012A1 (en) 2009-07-16
NO20051471L (no) 2005-05-23
WO2004017970A1 (en) 2004-03-04
ATE330605T1 (de) 2006-07-15
US20060025443A1 (en) 2006-02-02
CN1678316A (zh) 2005-10-05
KR20050038014A (ko) 2005-04-25
ES2268474T3 (es) 2007-03-16
UA80144C2 (uk) 2007-08-27
DE60306396D1 (de) 2006-08-03
EA200500242A1 (ru) 2005-08-25
AU2003255947A1 (en) 2004-03-11
GB0219639D0 (en) 2002-10-02
CY1105541T1 (el) 2010-07-28
CA2495377A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
ATE455756T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
DK1267866T3 (da) Behandling af respirationssygdomme
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
BRPI0514661B8 (pt) antagonistas de vasopressina v1a, composição farmacêutica e uso dos referidos antagonistas
MA29088B1 (fr) Composes d'indazole-carboxamide.
JP2008110984A5 (pt)
BR0312169A (pt) Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinação
BR9814280A (pt) Arilpiperazinas que apresentam atividade noreceptor 1a de serotonina
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
BRPI0417161A (pt) compostos, composições farmacêuticas, e, uso de um composto
BR0313674A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou a profilaxia de um distúrbio afetivo relacionado com a tensão
CY1105979T1 (el) Νεα οξινα θειικα αλατα πιπepιδινο-2,6-διονων και η χρηση τους για την αντιμετωπιση σχετιζομενων με το στρες συναισθηματικων διαταραχων
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
BRPI0809873A2 (pt) "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"
BR9815524A (pt) Piridilpirazóis substituìdos como herbicidas, inseticidas e acaricidas
BR0105787A (pt) Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico
BRPI0410127A (pt) derivados de pirimidina substituìdos
DE60013751D1 (de) Optisch aktive 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone als selektive 5-HT1D Rezeptor Antagonisten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]